Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
A E Ades a Department of Epidemiology and
Public Health, Institute of Child Health, London WC1N 1EH, b Department of Virology, Great Ormond Street Children's
Hospital NHS Trust, London WC1N 3JH, c Department of Genitourinary Medicine and
Communicable Diseases, Imperial College School of Medicine, St Mary's
Hospital, London W2 1PG
Correspondence to: A E Ades a.ades{at}ich.ucl.ac.uk
Objective:
To assess the prevalence of human T cell
leukaemia/lymphoma virus (HTLV) infection in pregnant women in the
United Kingdom.
Design:
Population study.
Subjects:
Guthrie card samples from babies born in
1997-8. Samples were linked to data on mother's age and ethnic status and parents' country of birth and then anonymised.
Setting:
North Thames Regional Health Authority.
Main outcome measures:
Presence of antibodies against
HTLV in eluates tested by gelatin particle agglutination assay and
results confirmed by immunoblot.
Results:
Of 126 010 samples tested, 67 had confirmed antibodies to HTLV (59 HTLV-I, 2 HTLV-II, 6 untyped) and six had indeterminate results. Seroprevalence was 17.0 per 1000 (95%
confidence interval 9.2 to 28.3) in infants whose mothers were born in
the Caribbean, 3.2/1000 (1.5 to 5.9) with mothers born in west and central Africa, and 6.8/1000 (3.1 to 12.9) in infants of black Caribbean mothers born in non-endemic regions. In infants with no known
risk (both parents born in non-endemic regions and mother not black
Caribbean) seroprevalence was 0.06-0.12 per 1000. Mother's country of
birth, father's country of birth, and mother's ethnic status were all
independently associated with neonatal seroprevalence. An estimated 223 (95% confidence interval 110 to 350) of the 720 000 pregnant women
each year in the United Kingdom are infected with HTLV.
Conclusions:
The prevalence of HTLV and HIV infections in pregnant women in the United Kingdom are comparable. The cost effectiveness of antenatal HTLV screening should be evaluated, and
screening of blood donations should be considered.